VTX958 + VTX958 + VTX958 Placebo

Phase 2Terminated
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease

Trial Timeline

Jan 25, 2023 → Dec 20, 2024

About VTX958 + VTX958 + VTX958 Placebo

VTX958 + VTX958 + VTX958 Placebo is a phase 2 stage product being developed by Ventyx Biosciences for Crohn Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05688852. Target conditions include Crohn Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05688852Phase 2Terminated

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
52
CT-P13 + RemicadeCelltrionPhase 3
77
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
85
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
23
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
33
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CP-461Astellas PharmaPhase 2
52
UstekinumabSun PharmaceuticalPre-clinical
23
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
41
E6011 + PlaceboEisaiPhase 2
52
E6011 + PlaceboEisaiPhase 1
33
adalimumab + adalimumab + placeboEisaiPhase 2/3
65
adalimumabEisaiPhase 2/3
65
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
77
MirikizumabEli LillyPhase 3
77
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
77
Mirikizumab + PlaceboEli LillyPhase 2
52
MirikizumabEli LillyPhase 3
77